1 / 6

Sofosbuvir + ( Ledipasvir or GS-9669) +/- Ribavirin in GT-1 ELECTRON Trial ( A rms 12-17 & 22)

Phase 2. Treatment Naïve and Treatment Experienced. Sofosbuvir + ( Ledipasvir or GS-9669) +/- Ribavirin in GT-1 ELECTRON Trial ( A rms 12-17 & 22). Source: Gane EJ, et al. Gastroenterogy . 2014 :146:736- 4 3.

september-harrington
Download Presentation

Sofosbuvir + ( Ledipasvir or GS-9669) +/- Ribavirin in GT-1 ELECTRON Trial ( A rms 12-17 & 22)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Phase 2 Treatment Naïve and Treatment Experienced Sofosbuvir + (Ledipasvir or GS-9669) +/- Ribavirin in GT-1ELECTRON Trial (Arms 12-17 & 22) Source: Gane EJ, et al. Gastroenterogy. 2014:146:736-43.

  2. Sofosbuvir + (Ledipasvir or GS-9669) +/- Ribavirin in GT1ELECTRON Trial (Arms 12-17 & 22): Features Source: Gane EJ, et al. Gastroenterogy. 2014:146:736-43.

  3. 0 6 12 18 24 Week Sofosbuvir + (Ledipasvir or GS-9669) +/- Ribavirin in GT1ELECTRON Trial Arms (12-17 & 22): Design n =25 SVR12 NoncirrhoticTreatment Naive LDV + SOF + RBV n = 25 SVR12 SOF + GS-9669 + RBV n = 25 LDV-SOF + RBV SVR12 n = 9 SVR12 NoncirrhoticNull responder LDV + SOF + RBV n = 10 SVR12 SOF + GS-9669 + RBV n = 10 SVR12 CirrhoticNull responder LDV-SOF n = 9 SVR12 LDV-SOF + RBV Abbreviations: LDV= ledipasvir; SOF = sofosbuvir; RBV = ribavirin Drug DosingSofosbuvir: 400 mg once daily; Ledipasvir: 90 mg once daily; GS-9669 = 500 mg once dailyLedipasvir-sofosbuvir (90/400 mg): fixed dose combination one pill once dailyRibavirin (weight-based and divided bid): 1000 mg/day if < 75kg or 1200 mg/day if ≥ 75kg Source: Gane EJ, et al. Gastroenterogy. 2014:146:736-43.

  4. Sofosbuvir + (Ledipasvir or GS-9669) +/- Ribavirin in GT1ELECTRON Trial (Arms 12-17 & 22): Results ELECTRON TRIAL, SVR 12 by Treatment Regimen 25/25 23/25 17/25 9/9 10/10 7/10 9/9 NoncirrhoticTreatment-Naive NoncirrhoticPrior Null Responder CirrhoticPrior Null Responder *All regimens 12 weeks except treatment-naïve LDV-SOF + Ribavirin= 6 week regimen Source: Gane EJ, et al. Gastroenterogy. 2014:146:736-43.

  5. Sofosbuvir + (Ledipasvir or GS-9669) +/- Ribavirin in GT1ELECTRON Trial (Arms 12-17 & 22): Conclusion Source: Gane EJ, et al. Gastroenterogy. 2014:146:736-43.

  6. This slide deck is from the University of Washington’s Hepatitis C Online and Hepatitis Web Study projects. Hepatitis C Onlinewww.hepatitisc.uw.edu Hepatitis Web Studyhttp://depts.washington.edu/hepstudy/ Funded by a grant from the Centers for Disease Control and Prevention.

More Related